Recursion Pharmaceuticals, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6.5M | 35.5M | 5.2M | 19.1M | 14.7M | 4.5M | 26.1M | 14.4M |
| Cost of Goods Sold | 12.5M | 26.9M | 29.6M | 20.2M | 21.8M | 12.8M | 12.1M | 9.2M |
| Gross Profit | -6.0M | 8.7M | -24.4M | -1.1M | -7.1M | -8.3M | 14.0M | 5.2M |
| R&D Expenses | 87.9M | 83.3M | 121.1M | 128.6M | 129.6M | 98.3M | 74.6M | 73.9M |
| Operating Expenses | 122.5M | 117.0M | 147.8M | 175.2M | 184.3M | 175.5M | 112.4M | 105.7M |
| Operating Income | -128.5M | -108.3M | -172.2M | -176.2M | -191.4M | -183.8M | -98.4M | -100.5M |
| Other Income / Gains | 6.4M | 232K | 10.0M | 4.3M | -11.3M | 4.9M | 2.7M | 2.5M |
| Net Income | -117.5M | -108.1M | -162.3M | -171.9M | -202.5M | -178.9M | -95.7M | -97.5M |
| EPS (Diluted) | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | -0.93 | 0.244 | -4.718 | -0.055 | -0.48 | -1.836 | 0.537 | 0.361 |
| General And Administrative Expenses | 34.6M | 33.7M | 41.6M | 46.7M | 54.6M | 77.2M | 37.8M | 31.8M |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 34.6M | 33.7M | 41.6M | 46.7M | 54.6M | 77.2M | 37.8M | 31.8M |
| Other Expenses | 0 | 0 | -14.9M | -120K | 0 | -35K | 0 | -13K |
| Cost And Expenses | 135.0M | 143.9M | 177.4M | 195.3M | 206.1M | 188.3M | 124.4M | 114.9M |
| Interest Income | 6.0M | 6.2M | 5.5M | 5.4M | 5.0M | 4.6M | 3.8M | 3.3M |
| Interest Expense | 350K | 0 | 833K | 480K | 0 | 605K | 553K | 394K |
| Depreciation And Amortization | 19.7M | 19.5M | 21.0M | 23.8M | 19.3M | 13.0M | 7.2M | 9.0M |
| Ebitda | -102.1M | -88.6M | -141.2M | -147.6M | -182.8M | -165.3M | -87.9M | -88.7M |
| Ebitdaratio | -15.773 | -2.494 | -27.286 | -7.725 | -12.398 | -36.653 | -3.371 | -6.158 |
| Operating Income Ratio | -19.856 | -3.048 | -33.276 | -9.225 | -12.979 | -40.738 | -3.771 | -6.98 |
| Income Before Tax | -122.1M | -108.1M | -162.3M | -171.9M | -202.6M | -178.9M | -95.7M | -98.1M |
| Income Before Tax Ratio | -18.867 | -3.042 | -31.353 | -8.998 | -13.743 | -39.658 | -3.668 | -6.808 |
| Income Tax Expense | -4.6M | 20K | 3K | 0 | -158K | 7K | 167K | -523K |
| Net Income Ratio | -18.156 | -3.042 | -31.353 | -8.998 | -13.733 | -39.66 | -3.668 | -6.772 |
| Epsdiluted | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 |
| Weighted Average Shs Out | 529.3M | 526.7M | 447.0M | 417.4M | 402.8M | 336.0M | 282.6M | 242.2M |
| Weighted Average Shs Out Dil | 529.3M | 526.7M | 447.0M | 417.4M | 402.8M | 336.0M | 282.6M | 242.2M |